Comparable stake leader
VANGUARD GROUP INC
SEC ownership of ATOSSA THERAPEUTICS, INC.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001488039.
Disclosed value leader
VANGUARD GROUP INC
Comparable rows
3/43
Latest evidence
30 Jun 2026
- Public ticker
- ATOS on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
VANGUARD GROUP INC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
3 of 43
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
VANGUARD GROUP INC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001488039
- Issuer location
- Seattle, WA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of ATOSSA THERAPEUTICS, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
VANGUARD GROUP INC
Disclosed value leader
VANGUARD GROUP INC
Comparable rows
3/43
Latest evidence
30 Jun 2026
13D/G
13F
3/4/5
Lead comparable stake: 4.5%
40 rows are not safely comparable across share classes.
13D/G row: VANGUARD GROUP INC
Showing 1-8 of 43 holder rows.
Quick read
VANGUARD GROUP INC leads the comparable SEC ownership view at 4.5%.
3 of 43 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens VANGUARD GROUP INC's linked filing trail.
Comparable ownership
Top 3
VANGUARD GROUP INC
4.5%
CVI Investments, Inc.
4.3%
BlackRock, Inc.
1.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 43 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| VANGUARD GROUP INC |
13D/G
The Vanguard Group
|
4.5%
|
$4,841,495
5,833,127 shares
|
$0 | 30 Jun 2025 |
| CVI Investments, Inc. |
13D/G
|
4.3%
|
$4,530,000
5,662,500 shares
|
$0 | 31 Dec 2024 |
| BlackRock, Inc. |
13D/G
13F
Company
|
1.6%
|
$1,717,392
2,094,891 shares
|
$0 | 30 Jun 2025 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
—
class O/S missing
|
$698,172
361,747 shares
|
— | 30 Jun 2026 |
| Steven C. Quay |
3/4/5
President & CEO, Director
|
—
mixed-class rows
|
$625,666
2,405,583 shares
mixed-class rows
|
— | 27 Mar 2026 |
| AMERIPRISE FINANCIAL INC |
13F
Company
|
—
class O/S missing
|
$498,392
258,234 shares
|
— | 30 Jun 2026 |
| RENAISSANCE TECHNOLOGIES LLC |
13F
Company
|
—
class O/S missing
|
$254,843
132,043 shares
|
— | 30 Jun 2026 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
—
class O/S missing
|
$178,343
92,382 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 05 Sep 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-11 of 11 reporting-owner rows connected to ATOSSA THERAPEUTICS, INC.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
11
Largest Forms 3/4/5 holder
Steven C. Quay
Net 12M change
$0
Latest report
12 May 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Steven C. Quay | President & CEO, Director | $625,666 | Mixed | 27 Mar 2026 | ||
| Mark James Daniel | Chief Financial Officer | $37,170 | Mixed | 26 Mar 2026 | ||
| Jonathan Finn | Director | $10,263 | Mixed | 12 May 2026 | ||
| Shu-Chih Chen | Director | $10,102 | Mixed | 12 May 2026 | ||
| Stephen J. Galli | Director | $8,802 | Mixed | 12 May 2026 | ||
| Tessa Cigler | Director | $8,797 | Mixed | 12 May 2026 | ||
| Richard I. Steinhart | Director | $8,797 | Mixed | 12 May 2026 | ||
| H. Lawrence Remmel | Director | $7,180 | Mixed | 12 May 2026 | ||
| Gregory L. Weaver | Former EVP, CFO, & Director, Director | $36 | Filing P/S | 15 Nov 2023 | ||
| Kyle Guse | CFO, Gen Counsel and Secretary | Mixed | 02 Mar 2023 | |||
| Heather Rees | Chief Financial Officer | Mixed | 15 May 2025 |
Recent insider transactions for ATOSSA THERAPEUTICS, INC.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Richard I. Steinhart | ATOS | Common Stock | Award | 10,000 | 10,000 | 12 May 2026 | Direct | |||
| Shu-Chih Chen | ATOS | Common Stock | Award | 10,000 | 10,000 | 12 May 2026 | Direct | |||
| H. Lawrence Remmel | ATOS | Common Stock | Award | 1464.1% | 10,000 | 10,683 | 12 May 2026 | Direct | ||
| Jonathan Finn | ATOS | Common Stock | Award | 600.2% | 10,000 | 11,666 | 12 May 2026 | Direct | ||
| Stephen J. Galli | ATOS | Common Stock | Award | 166666.7% | 10,000 | 10,006 | 12 May 2026 | Direct | ||
| Tessa Cigler | ATOS | Common Stock | Award | 10,000 | 10,000 | 12 May 2026 | Direct | |||
| Steven C. Quay | ATOS | Common Stock | Award | 282.1% | 65,000 | 88,038 | 27 Mar 2026 | Direct | ||
| Mark James Daniel | ATOS | Common Stock | Award | 63,000 | 63,000 | 26 Mar 2026 | Direct | |||
| Steven C. Quay | ATOS | Common Stock | Award | 2386.5% | 331,674 | 345,572 | 20 Jan 2026 | Direct | ||
| Steven C. Quay | ATOS | Stock Options (right to buy) | Award | 950,000 | 950,000 | 20 Jan 2026 | Direct | |||
| Mark James Daniel | ATOS | Stock Option (right to buy) | Award | 578,000 | 578,000 | 14 Oct 2025 | Direct |
* marks a reported price that did not pass the local price check.